$13.960
-0.148 (-1.06%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de DRTS por análisis de gráficos similares
Alphio's DRTS stock price prediction model matches the current Alpha Tau Medical Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $14.03 (+0.51%). The 1-week path is $13.76 (-1.44%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Alpha Tau Medical Ltd?
Alpha Tau Medical Ltd (DRTS) is a good buy right now, trading at $14.64 with a strong year-to-date change of +203.11%. The RSI is at 56.24, indicating a healthy momentum. Analyst price targets suggest a potential upside of 9% to 16% based on recent upgrades, with H.C. Wainwright targeting $16 and Barclays at $17. The main risk is the negative EPS trend, with a reported EPS of -0.50, reflecting ongoing losses, but the dual listing and FDA approvals could drive future growth.
DRTS cerró en $13.96 el Tuesday, tras bajar -1.06%
Alpha Tau Medical Ltd (DRTS) last closed at $13.96, losing -1.06%. These facts feed the 1-day and 1-week DRTS price prediction above.
Factores de la previsión
Los factores de la previsión de Alpha Tau Medical Ltd (DRTS) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bullish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de DRTS, ordenadas por similitud.
Análisis de estacionalidad de DRTS
Historically the probability of a positive September return for DRTS is 52.38%. December offers the highest probability of a positive month at 93.02%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.